Search Result

Results for "

thrombotic diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (6) Amino Acid Derivatives (1) Apoptosis (2) Calcium Channel (1) Caspase (1) Cathepsin (1) COX (2) Drug Derivative (1) Endogenous Metabolite (4) Environmental Pollutants (2) ERK (3) Factor Xa (3) Factor XI (1) GLP Receptor (1) HIF/HIF Prolyl-Hydroxylase (2) Integrin (3) Interleukin Related (3) Isotope-Labeled Compounds (4) JAK (1) JNK (2) LDLR (1) Liposome (2) Lipoxygenase (1) MMP (1) p38 MAPK (2) PAI-1 (2) PI3K (6) PKC (1) PPAR (1) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (3) Reference Standards (3) RSV (2) Ser/Thr Protease (1) STAT (1) Thrombin (7)
By Research Areas:	Cancer (10) Cardiovascular Disease (37) Endocrinology (1) Infection (3) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (1)

By Targets:

Akt (6)

Amino Acid Derivatives (1)

Apoptosis (2)

Calcium Channel (1)

Caspase (1)

Cathepsin (1)

COX (2)

Drug Derivative (1)

Endogenous Metabolite (4)

Environmental Pollutants (2)

ERK (3)

Factor Xa (3)

Factor XI (1)

GLP Receptor (1)

HIF/HIF Prolyl-Hydroxylase (2)

Integrin (3)

Interleukin Related (3)

Isotope-Labeled Compounds (4)

JAK (1)

JNK (2)

LDLR (1)

Liposome (2)

Lipoxygenase (1)

MMP (1)

p38 MAPK (2)

PAI-1 (2)

PI3K (6)

PKC (1)

PPAR (1)

Prostaglandin Receptor (2)

Protease Activated Receptor (PAR) (3)

Reference Standards (3)

RSV (2)

Ser/Thr Protease (1)

STAT (1)

Thrombin (7)

By Research Areas:

Cancer (10)

Cardiovascular Disease (37)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (11)

Metabolic Disease (5)

Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0728

α-Linolenic acid Maximum Cited Publications 11 Publications Verification ALA free base; C18:3 (9Z,12Z,15Z) free base; C18:3 n-3 free base	Environmental Pollutants Akt PI3K	Cardiovascular Disease Cancer
α-Linolenic acid (ALA (free base); C18:3 (9Z,12Z,15Z) (free base); C18:3 n-3 (free base)) is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-P1929

Bivalirudin Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-15468

IOX2 Maximum Cited Publications 18 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
IOX2, a chemical probe, is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC₅₀ of 22 nM. IOX2 regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 can be used in the study of thrombotic diseases .

HY-N0728S3

α-Linolenic acid-13C18	Isotope-Labeled Compounds PI3K Akt	Cardiovascular Disease Cancer
α-Linolenic acid- ¹³C₁₈ is the ¹³C labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-P99505

Ziltivekimab COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216	Interleukin Related LDLR	Inflammation/Immunology Endocrinology
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .

HY-W011690

L-Homocystine	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.

HY-15664

Bivalirudin TFA Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Liposome	Cardiovascular Disease
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-W089800

trans-2-Nonenal trans-2-Nonen-1-al	COX Lipoxygenase Apoptosis	Cardiovascular Disease Inflammation/Immunology
trans-2-Nonenal (trans-2-Nonen-1-al) is an endogenous peroxidation product of polyunsaturated fatty acids, acting as an inhibitor of COX and 12-LOX, as well as an inducer of apoptosis. trans-2-Nonenal is also a malodorous compound secreted by the human body, and its content gradually increases with aging. trans-2-Nonenal inhibits the activities of multiple enzymes such as platelet membrane-bound PTPase, preferentially covalently modifies proteins at lysine residues to form immunogenic adducts, and regulates platelet Arachidonic acid (HY-109590) metabolism. trans-2-Nonenal also exhibits significant cytotoxicity, reduces the viability of keratinocytes, promotes their apoptosis, and effectively decreases the thickness of epidermal models and the number of proliferating cells. trans-2-Nonenal is commonly used in studies of thrombotic, atherosclerotic diseases, renal adenocarcinoma, etc. .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Thrombin COX ERK JNK Factor Xa	Cardiovascular Disease Inflammation/Immunology
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-N0728S

α-Linolenic acid-d5	Isotope-Labeled Compounds PI3K Akt	Cardiovascular Disease Cancer
α-Linolenic acid-d₅ is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-P3012

Cathepsin G	Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP	Inflammation/Immunology
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .

HY-N2452

Cochinchinenin C	GLP Receptor	Cardiovascular Disease Infection Metabolic Disease
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .

HY-N0728R

α-Linolenic acid (Standard) Maximum Cited Publications 11 Publications Verification	Reference Standards PI3K Akt	Cardiovascular Disease Cancer
α-Linolenic acid (Standard) is the analytical standard of α-Linolenic acid. This product is intended for research and analytical applications. α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-W004283R

Pentadecanoic acid (Standard)	Reference Standards Endogenous Metabolite JAK STAT PPAR p38 MAPK JNK ERK Caspase Apoptosis	Metabolic Disease Cancer
α-Linolenic acid (Standard) is the analytical standard of α-Linolenic acid. This product is intended for research and analytical applications. α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-W011690S

L-Homocystine-d8	Endogenous Metabolite	Metabolic Disease
L-Homocystine-d₈ is the deuterium labeled L-Homocystine. L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.

HY-N0728A

α-Linolenic acid sodium 10+ Cited Publications ALA; C18:3 (9Z,12Z,15Z); C18:3 n-3	Environmental Pollutants Akt PI3K	Cardiovascular Disease Cancer
α-Linolenic acid sodium (ALA; C18:3 (9Z,12Z,15Z); C18:3 n-3) is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid sodium can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid sodium possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-19660

Inogatran H-314-27	Thrombin	Cardiovascular Disease
Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

HY-P991124

Cenvacibart REGN-7508	Factor XI	Cardiovascular Disease
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .

HY-105866

Wy 27569	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease
Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic TXA2, and increase anti thrombotic PGI2. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina .

HY-10594

Letaxaban TAK-442	Factor Xa	Cardiovascular Disease Inflammation/Immunology
Letaxaban (TAK-442) is an orally active and selective direct FXa inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting FXa and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases .

HY-172905

BCX-3607	Others	Cardiovascular Disease
BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC₅₀: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases .

HY-19229

TAK-029	Integrin	Cardiovascular Disease
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .

HY-129786

LG 82-4-00	Prostaglandin Receptor	Cardiovascular Disease
LG 82-4-00 is a thromboxane (TX) synthase inhibitor with an IC₅₀ value of 1.1 μM. LG 82-4-00 can inhibit collagen-induced TXB₂ formation and platelet aggregation in plasma. LG 82-4-00 can be used in studies related to thrombotic diseases .

HY-143313

Protease-Activated Receptor-1 antagonist 1	Protease Activated Receptor (PAR)	Cardiovascular Disease
Protease-Activated Receptor-1 antagonist 1 (Compound 13) is a protease-activated receptor-1 (PAR-1) antagonist with the IC₅₀ of 3 nM by FLIPR technology. Protease-Activated Receptor-1 antagonist 1 can be used for the research of thrombotic cardiovascular, myocardial infarction, and peripheral arterial disease .

HY-163685

Bisobrin EN-1661	Others	Others
Bisobrin (EN-1661) is a synthetic compound that may affect the thrombolytic system to promote thrombolysis and thereby play a role in inhibiting thrombotic diseases .

HY-10725

Tanogitran	Factor Xa	Cardiovascular Disease
Tanogitran is a dual inhibitor targeting Factor Xa and thrombin (thrombin), with K_i values of 26 and 2.7 nM, respectively. Tanogitran exhibits anticoagulant activity and can be used for research in thrombotic diseases .

HY-169836

Des-ethyl-carafiban	Integrin	Cardiovascular Disease
Des-ethyl-carafiban (Compound 44) is a fibrinogen receptor antagonist that can effectively inhibit platelet aggregation induced by multiple agonists. Des-ethyl-carafiban can be used in the research of thrombotic diseases .

HY-W091734

Methyl 4-iodo-L-phenylalaninate hydrochloride	Amino Acid Derivatives	Cardiovascular Disease Neurological Disease
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .

HY-162109

Thrombin inhibitor 11	Thrombin	Cardiovascular Disease
Thrombin inhibitor 11 is an orally active, competitive and selective α-Thrombin inhibitor, with a K_i value of 65 nM against h-αThrombin and a K_i value of 10.3 nM against rat-derived α-thrombin. Thrombin inhibitor 11 can be used for the research of thrombotic diseases .

HY-15468A

IOX2 sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
IOX2 sodium is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC₅₀ of 22 nM. IOX2 sodium regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 sodium can be used in the study of thrombotic diseases .

HY-P2830

Complement factor D	Ser/Thr Protease	Inflammation/Immunology
Complement factor D is a serine protease. Complement factor D activates C3 convertase by specifically cleaving complement Factor B. Complement factor D is promising for research of autoimmune diseases (e.g., paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy), age-related macular degeneration, and thrombotic microangiopathies .

HY-117537

XR 5118 hydrochloride	PAI-1	Cardiovascular Disease Cancer
XR 5118 hydrochloride is an inhibitor of plasminogen activator inhibitor 1 (PAI-1) (IC₅₀: 12 µM). XR5118 binds to PAI-1 and reduces plasma PAI-1 activity levels. XR5118 hydrochloride promotes endogenous thrombolysis and inhibits thrombus accretion. XR 5118 hydrochloride can be used for research of cancer and thrombotic disease .

HY-N0728S2

α-Linolenic acid-d14	Isotope-Labeled Compounds PI3K Akt	Cardiovascular Disease Cancer
α-Linolenic acid-d₁₄ is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-126356S

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d11	Isotope-Labeled Compounds Liposome	Cardiovascular Disease
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d₁₁ is the deuterium labeled 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (HY-126356). 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-113769

WB 3559 A	PAI-1	Cardiovascular Disease
WB 3559 A is a fibrinolytic plasminogen activator. WB 3559 A accelerates the conversion of plasminogen to plasmin and directly degrades fibrin in thrombi. WB 3559 A is promising for research of acute thrombotic diseases (e.g., myocardial infarction, pulmonary embolism) .

HY-10312

UR-12947	Integrin	Cardiovascular Disease
UR-12947 is a platelet glycoprotein (GP) IIb-IIIa antagonist. UR-12947 exhibits potent inhibitory activity against platelet aggregation in human platelet-rich plasma, with an IC₅₀ value of 3.5 nM. UR-12947 can be used in the research of arterial thrombotic diseases .

HY-105514

KP-10614	Drug Derivative	Cardiovascular Disease
KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC₅₀ of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research .

HY-W011690R

L-Homocystine (Standard)	Endogenous Metabolite Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
L-Homocystine (Standard) is the analytical standard of L-Homocystine (HY-W011690). This product is intended for research and analytical applications. L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.

HY-105363

RGH-1962	Others	Cardiovascular Disease
RGH-1962 is an orally active antithrombotic agent. RGH-1962 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1962 can be used for the study of thrombotic diseases .

HY-165360

JJ1	Thrombin	Cardiovascular Disease
JJ1 is a selective α-thrombin inhibitor with a K_i of 0.019 μM. JJ1 directly binds to the active site of α-thrombin to block its catalytic activity. JJ1 exhibits antithrombotic effects and prolongs activated partial thromboplastin time, prothrombin time, and tail bleeding time in mice. JJ1 can be used for the research of thrombotic diseases .

HY-105364

RGH-1875 hydriodide GYKI 39521 hydriodide	Others	Cardiovascular Disease
RGH-1875 (GYKI 39521) hydriodide is the hydriodide of RGH-1875. RGH-1875 is an orally active antithrombotic agent. RGH-1875 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1875 can be used for the study of thrombotic diseases .

HY-182573

RWJ-58259	Protease Activated Receptor (PAR)	Cardiovascular Disease
RWJ-58259 is a selective PAR-1 inhibitor with an IC₅₀ value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention .

Cat. No.	Product Name	Type

HY-W089800

trans-2-Nonenal trans-2-Nonen-1-al	Biochemical Assay Reagents
trans-2-Nonenal (trans-2-Nonen-1-al) is an endogenous peroxidation product of polyunsaturated fatty acids, acting as an inhibitor of COX and 12-LOX, as well as an inducer of apoptosis. trans-2-Nonenal is also a malodorous compound secreted by the human body, and its content gradually increases with aging. trans-2-Nonenal inhibits the activities of multiple enzymes such as platelet membrane-bound PTPase, preferentially covalently modifies proteins at lysine residues to form immunogenic adducts, and regulates platelet Arachidonic acid (HY-109590) metabolism. trans-2-Nonenal also exhibits significant cytotoxicity, reduces the viability of keratinocytes, promotes their apoptosis, and effectively decreases the thickness of epidermal models and the number of proliferating cells. trans-2-Nonenal is commonly used in studies of thrombotic, atherosclerotic diseases, renal adenocarcinoma, etc. .

trans-2-Nonenal

trans-2-Nonen-1-al

Biochemical Assay Reagents

trans-2-Nonenal (trans-2-Nonen-1-al) is an endogenous peroxidation product of polyunsaturated fatty acids, acting as an inhibitor of COX and 12-LOX, as well as an inducer of apoptosis. trans-2-Nonenal is also a malodorous compound secreted by the human body, and its content gradually increases with aging. trans-2-Nonenal inhibits the activities of multiple enzymes such as platelet membrane-bound PTPase, preferentially covalently modifies proteins at lysine residues to form immunogenic adducts, and regulates platelet Arachidonic acid (HY-109590) metabolism. trans-2-Nonenal also exhibits significant cytotoxicity, reduces the viability of keratinocytes, promotes their apoptosis, and effectively decreases the thickness of epidermal models and the number of proliferating cells. trans-2-Nonenal is commonly used in studies of thrombotic, atherosclerotic diseases, renal adenocarcinoma, etc. .

Cat. No.	Product Name	Target	Research Area

HY-P1929

Bivalirudin Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-15664

Bivalirudin TFA Maximum Cited Publications 9 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-P3012

Cathepsin G	Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP	Inflammation/Immunology
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .

HY-P10918

F11R peptide TFA	Peptides	Inflammation/Immunology
F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelial cells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease .

HY-W091734

Methyl 4-iodo-L-phenylalaninate hydrochloride	Amino Acid Derivatives	Cardiovascular Disease Neurological Disease
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99505

Ziltivekimab COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216	Interleukin Related LDLR	Inflammation/Immunology Endocrinology
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .

HY-P991124

Cenvacibart REGN-7508	Factor XI	Cardiovascular Disease
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0728

α-Linolenic acid Maximum Cited Publications 11 Publications Verification ALA free base; C18:3 (9Z,12Z,15Z) free base; C18:3 n-3 free base	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Labiatae Ulex europaeus L. Disease markers Plants Endogenous metabolite Disease Research Fields Cardiovascular System Disorder Source Classification	Environmental Pollutants Akt PI3K
α-Linolenic acid (ALA (free base); C18:3 (9Z,12Z,15Z) (free base); C18:3 n-3 (free base)) is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-W011690

L-Homocystine	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Liposome
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-W089800

trans-2-Nonenal trans-2-Nonen-1-al	Source Classification	COX Lipoxygenase Apoptosis
trans-2-Nonenal (trans-2-Nonen-1-al) is an endogenous peroxidation product of polyunsaturated fatty acids, acting as an inhibitor of COX and 12-LOX, as well as an inducer of apoptosis. trans-2-Nonenal is also a malodorous compound secreted by the human body, and its content gradually increases with aging. trans-2-Nonenal inhibits the activities of multiple enzymes such as platelet membrane-bound PTPase, preferentially covalently modifies proteins at lysine residues to form immunogenic adducts, and regulates platelet Arachidonic acid (HY-109590) metabolism. trans-2-Nonenal also exhibits significant cytotoxicity, reduces the viability of keratinocytes, promotes their apoptosis, and effectively decreases the thickness of epidermal models and the number of proliferating cells. trans-2-Nonenal is commonly used in studies of thrombotic, atherosclerotic diseases, renal adenocarcinoma, etc. .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Cardiovascular Disease Flavonols Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification	Thrombin COX ERK JNK Factor Xa
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-N2452

Cochinchinenin C	other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	GLP Receptor
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .

HY-N0728R

α-Linolenic acid (Standard) Maximum Cited Publications 11 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Ulex europaeus L. Plants Endogenous metabolite Microorganisms Labiatae Disease markers Disease Research Fields Cardiovascular System Disorder Source Classification	Reference Standards PI3K Akt
α-Linolenic acid (Standard) is the analytical standard of α-Linolenic acid. This product is intended for research and analytical applications. α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-W004283R

Pentadecanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite JAK STAT PPAR p38 MAPK JNK ERK Caspase Apoptosis
α-Linolenic acid (Standard) is the analytical standard of α-Linolenic acid. This product is intended for research and analytical applications. α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-W011690R

L-Homocystine (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
L-Homocystine (Standard) is the analytical standard of L-Homocystine (HY-W011690). This product is intended for research and analytical applications. L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.

Cat. No.	Product Name	Chemical Structure

HY-N0728S3

α-Linolenic acid-13C18
α-Linolenic acid- ¹³C₁₈ is the ¹³C labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-N0728S

α-Linolenic acid-d5
α-Linolenic acid-d₅ is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-W011690S

L-Homocystine-d8
L-Homocystine-d₈ is the deuterium labeled L-Homocystine. L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.

HY-N0728S2

α-Linolenic acid-d14
α-Linolenic acid-d₁₄ is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer .

HY-126356S

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d11

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d₁₁ is the deuterium labeled 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (HY-126356). 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

thrombotic diseases

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products